Testing a new medicine for fatty liver disease in teens with obesity
Treatments studied
Part of Digestive system clinical trials.
This study tests whether a medicine called empagliflozin (a type of SGLT2 inhibitor) can help treat non-alcoholic fatty liver disease in adolescents with obesity. It aims to see if the drug can reduce fat in the liver and improve liver health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 20 years old.
- You have obesity (BMI in the 95th percentile or higher for your age and sex, or BMI of 30 or more).
- You have had high liver enzymes (ALT) or a diagnosis of fatty liver disease (NAFLD) in the past.
- You are willing to follow lifestyle guidance during the study (like diet and exercise).
- You do not have diabetes or prediabetes (your fasting blood sugar is less than 100 mg/dL).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication called empagliflozin (a type of SGLT2 inhibitor) to see if it can help treat fatty liver disease in teenagers and young adults. It may improve liver health and help with weight management.
This study looks at why “nonalcoholic fatty liver disease” happens in teenagers and how it develops. It may help doctors better predict and prevent liver problems in children, even if there isn’t a new drug for you to take.
This study looks at how fructose (a type of sugar) may affect fatty liver disease (NAFLD) in teens with obesity. The goal is to learn whether fructose changes liver health, using MRI/MRS scans to measure the liver.
This trial tests a medication called SGLT2 inhibitor (a type of diabetes drug that may also help protect the kidneys) in children with chronic kidney disease. It aims to see if the drug is safe and easy to use in children ages 2–18 with moderate to severe kidney problems.
This trial tests a diabetes drug called empagliflozin to see if it can reduce fat and inflammation in the liver in people with a specific type of fatty liver disease called NASH. It may help if you have NASH and either have type 2 diabetes or don't have it.
This trial studies whether erugliflozin can reduce liver fat and liver scarring (fibrosis) while also improving blood sugar in people with type 2 diabetes and fatty liver disease (NASH/NAFLD). It’s designed for people who haven’t used certain diabetes medicines like SGLT2 inhibitors or insulin before.
Hear when a new NAFLD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.